CA3099527A1 - Multispecific binders of tgf.beta.-superfamily ligands and uses thereof - Google Patents

Multispecific binders of tgf.beta.-superfamily ligands and uses thereof Download PDF

Info

Publication number
CA3099527A1
CA3099527A1 CA3099527A CA3099527A CA3099527A1 CA 3099527 A1 CA3099527 A1 CA 3099527A1 CA 3099527 A CA3099527 A CA 3099527A CA 3099527 A CA3099527 A CA 3099527A CA 3099527 A1 CA3099527 A1 CA 3099527A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099527A
Other languages
English (en)
French (fr)
Inventor
Ravindra Kumar
Dianne S. Sako
Roselyne CASTONGUAY
Tzu-Hsing KUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA3099527A1 publication Critical patent/CA3099527A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3099527A 2018-05-03 2019-05-02 Multispecific binders of tgf.beta.-superfamily ligands and uses thereof Pending CA3099527A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666547P 2018-05-03 2018-05-03
US62/666,547 2018-05-03
US201862779998P 2018-12-14 2018-12-14
US62/779,998 2018-12-14
PCT/US2019/030469 WO2019213442A1 (en) 2018-05-03 2019-05-02 MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3099527A1 true CA3099527A1 (en) 2019-11-07

Family

ID=68386158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099527A Pending CA3099527A1 (en) 2018-05-03 2019-05-02 Multispecific binders of tgf.beta.-superfamily ligands and uses thereof

Country Status (6)

Country Link
US (2) US12103959B2 (enExample)
EP (1) EP3788066A4 (enExample)
JP (1) JP2021522793A (enExample)
AU (1) AU2019262139A1 (enExample)
CA (1) CA3099527A1 (enExample)
WO (1) WO2019213442A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021119136A1 (en) * 2019-12-10 2021-06-17 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension
CA3196443A1 (en) * 2020-11-04 2022-05-12 Hq Han Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
US20240277807A1 (en) * 2021-06-11 2024-08-22 Acceleron Pharma Inc. Actrii proteins and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
US10358476B2 (en) 2015-04-06 2019-07-23 Acceleron Pharma Inc. Single arm type I and type II receptor fusion proteins and uses thereof
MA41920B1 (fr) * 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
CA3029890A1 (en) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
AU2017338915B2 (en) * 2016-10-05 2024-11-21 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
CN110036025B (zh) 2016-10-05 2024-03-22 阿塞勒隆制药公司 变体ActRIIB蛋白及其用途
CN206301918U (zh) * 2016-12-23 2017-07-04 深圳国人通信股份有限公司 一种介质移相器
US12168683B2 (en) 2018-05-03 2024-12-17 Acceleron Pharma Inc. Binders of TGFβ-superfamily ligands and uses thereof
CA3103427A1 (en) 2018-06-15 2019-12-19 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof

Also Published As

Publication number Publication date
EP3788066A1 (en) 2021-03-10
EP3788066A4 (en) 2022-01-26
US12103959B2 (en) 2024-10-01
US20250109179A1 (en) 2025-04-03
AU2019262139A1 (en) 2020-11-26
JP2021522793A (ja) 2021-09-02
US20220372107A1 (en) 2022-11-24
WO2019213442A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
US11827689B2 (en) ALK7:ActRIIB heteromultimers and uses thereof
US12258380B2 (en) ALK4:actriib heteromultimers and uses thereof
US12024563B2 (en) ALK7 antagonists and uses thereof
EP3576773B1 (en) Tgf beta and actrii antagonists for use in treating leukemia
US9452197B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
CA3014197A1 (en) Actrii antagonists for use in increasing immune activity
US20250333477A1 (en) Novel binders of tgfb-superfamily ligands and uses thereof
US20250109179A1 (en) MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF
JP2018510637A (ja) フォリスタチン関連融合タンパク質およびその使用
JP2019527547A (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
CA3103427A1 (en) Bi-and tri-functional fusion proteins and uses thereof
CN116134049A (zh) 变体actriib蛋白及其用途
KR102776403B1 (ko) Cd80 단백질 돌연변이체 및 그 응용
CA3211515A1 (en) Actrii-alk4 antagonists and methods of treating heart failure

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251017

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251217